Multivalent Pcv2 Immunogenic Compositions And Methods Of Producing Such Compositions
Patent No. EP3868400 (titled "Multivalent Pcv2 Immunogenic Compositions And Methods Of Producing Such Compositions") was filed by Hring on Dec 28, 2006. The application was issued on May 13, 2026.
Patent Summary
A multivalent combination vaccine for swine comprises 2 µg to 50 µg of PCV2 ORF2 protein per dose and at least one immunogenic active component targeting another swine disease-causing organism. The vaccine is used in a method to lessen the severity of clinical symptoms associated with PCV2 infection, such as Post-weaning Multisystemic Wasting Syndrome (PMWS), via a single administration. The PCV2 ORF2 protein may be a recombinant protein expressed by a transfected virus and recovered from the supernate. Target organisms for the additional immunogenic components include PRRS virus, *Lawsonia intracellularis*, BVD, *Leptospira* serovars, *Brucella suis*, *Clostridium* species (*C. difficile, C. perfringens, C. novyi*), *Eperythrozoon suis*, adenovirus, and hemagglutinating encephalomyelitis virus.
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents
EP3868400
- Application Number
- EP21159529A
- Filing Date
- Dec 28, 2006
- Status
- Granted And Under Opposition
- Apr 10, 2026
- Publication Date
- May 13, 2026
- External Links
- Slate, Register , Google Patents